2005
DOI: 10.1007/s00280-004-0983-y View full text |Buy / Rent full text
|
|

Abstract: The recommended dose was determined as 80 mg/m2 of paclitaxel (days 1 and 8) and 800 mg/m2) of doxifluridine (days 1-14) every 3 weeks. The results of this phase I study are encouraging and a phase II trial is thus warranted.

Help me understand this report

Search citation statements

Order By: Relevance
Select...
3
1
1
0
10
0

Year Published

2007
2007
2011
2011

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

0
10
0
Order By: Relevance
“…Based on the results of these experiments, Moriwaki et al reported the results of a phase I study regarding combination therapy with paclitaxel and doxifluridine for gastric cancer (10). In their study, 22 of 28 patients were pretreated with 5-FU or S-1.…”
Section: Discussionmentioning
See 1 more Smart Citation
Create an account to read the remaining citation statements from this report. You will also get access to:
  • Search over 1.2b+ citation statments to see what is being said about any topic in the research literature
  • Advanced Search to find publications that support or contrast your research
  • Citation reports and visualizations to easily see what publications are saying about each other
  • Browser extension to see Smart Citations wherever you read research
  • Dashboards to evaluate and keep track of groups of publications
  • Alerts to stay on top of citations as they happen
  • Automated reference checks to make sure you are citing reliable research in your manuscripts
  • 7 day free preview of our premium features.

Trusted by researchers and organizations around the world

Over 130,000 students researchers, and industry experts at use scite

See what students are saying

rupbmjkragerfmgwileyiopcupepmcmbcthiemesagefrontiersapsiucrarxivemeralduhksmucshluniversity-of-gavle
“…Based on the results of these experiments, Moriwaki et al reported the results of a phase I study regarding combination therapy with paclitaxel and doxifluridine for gastric cancer (10). In their study, 22 of 28 patients were pretreated with 5-FU or S-1.…”
Section: Discussionmentioning
“…Based on the results, we determined the dose and schedule of this study (10). The two drugs were administered as follows: paclitaxel (Taxol; Bristol-Myers Squibb Company, Tokyo, Japan) 80 mg/m 2 over 60 min iv infusion on day 1 and 8; doxifluridine (Fulturon; Chugai Pharmaceutical Company, Tokyo, Japan) 600 mg/m 2 /day po on days 1 -14.…”
Section: Treatment Schedule and Evaluation Of Toxicitymentioning
“…25 After being activated by thymidine phosphorylase, doxifl uridine may act synergistically with paclitaxel, even in patients unresponsive to TS-1. Clinical phase I trials of doxifl uridine plus weekly paclitaxel as fi rst-line treatment for advanced or recurrent gastric cancer have been performed, 10,11 and a good response has been documented in case reports. 26 On the basis of the results of these experimental and clinical studies, we used a combination of doxifl uridine and weekly paclitaxel for second-line chemotherapy in patients who did not respond to or had recurrence with TS-1.…”
Section: Discussionmentioning
“…9 Two phase I clinical trials of doxifl uridine combined with weekly paclitaxel as fi rstline therapy for gastric cancer have provided preliminary information on recommended dosage and response rates. 10,11 We report the results of clinical studies of combination therapy with doxifl uridine and weekly paclitaxel in patients with gastric cancer who had to discontinue therapy with TS-1.…”
Section: Introductionmentioning
“…Moreover, PTX in combination with 5'-DFUR has shown synergistic activity in preclinical studies (Sawada et al 2005), and 5'-DFUR may act synergistically with PTX, even in patients unresponsive to TS-1. Moriwaki et al designed a phase I study examining PTX and 5 0 -DFUR combination therapy for gastric cancer and recommended doses of 80 mg/m 2 PTX (days 1 and 8) and 800 mg/m 2 5 0 -DFUR (days 1-14) every 3 weeks (Moriwaki et al 2005). Based on their study, we determined the safety and feasibility of PTX plus 5 0 -DFUR combination therapy as second-line chemotherapy for elderly patients (C70 years old) with URGC.…”
Section: Discussionmentioning